Patients with hepatitis C virus-related cirrhosis who respond well to anti-viral treatment, the survival rate equal to the general population, such as investigators Chinese Journal of Hepatology.
Cirrhosis and liver dysfunction, such as decompensated liver cancer or long-term development infected with hepatitis C virus (HCV) still represents the leading cause of death after in Western countries and liver transplantation. The current international guidelines highest priority for new direct antivirals, who have developed cirrhosis of the liver with HCV infection treatment. This recommendation is based on who gets favorable results are based on interferon therapy after sustained virologic response (SVR) in patients with cirrhosis. However, it has been proposed in this recommendation is based on evidence of whether strong enough.
“To improve the prognosis of patients who had a sustained virologic response is only by comparing patients who were unsuccessful with similar patients who are treated based on the reaction of interferon therapy, to improve the SVR as a real concern value recorded up to now the disease reliable marker outcome, explains: “the principal investigator Bruno Savino, MD, University and Humanitas IRCCS Istituto Clínico hospital Humanitas, Rozzano, Italy.
Investigators from Italy compensatory cases of hepatitis C virus-related cirrhosis who underwent liver centers in the three interferon-based treatment, and achieved sustained virologic response (SVR) Prospective monitoring data of three independent research teams, as well as with the observation non-SVR, relatively untreated and decompensated patients. They excluded patients with non-cirrhotic advanced fibrosis.
Overall, 795 of 1802 patients with HCV-related cirrhosis receiving interferon-based antiviral therapy in three groups. A total of 181 cases of patients achieved SVR. HCV- patients with decompensated cirrhosis who achieved SVR survival is similar to the sex and age-matched general population, a total of 28 people were killed. The entire series of 10-year overall survival rate of 90%, 20-year survival rate was 63%.
“These results confirm that, who based on interferon therapy patients had similar reactions and life expectancy of the general population, and recommended that treatment should be to achieve maximum benefit in patients with compensated HCV cirrhosis administered as soon as possible,” comments Dr. Bruno. “Health freedom interferon new direct antivirals (DAA) program will allow even sicker patients and those who are not eligible interferon achieve SVR, the light of mortality in these patients is very high compared to the general population is a big step forward, but, SVR overall impact needs further study, devoted to the assessment. “